IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k

7 years ago

IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07.

Submission of Matters to a Vote of Security Holders.

Ionis Pharmaceuticals, Inc. (the Company) held its Annual Meeting
of Stockholders on May 24, 2017. The stockholders considered five
proposals, each of which is described in more detail in the
Companys definitive proxy statement dated April 6, 2017.

Proposal 1:

Election of directors to hold office until the 2020
Annual Meeting:

	FOR	WITHHELD	BROKER NON-VOTES
Spencer R. Berthelsen	84,173,655	9,020,996	21,105,539
B. Lynne Parshall	87,494,494	5,700,157	21,105,539
Joseph H. Wender	84,148,943	9,045,708	21,105,539

The Companys stockholders elected the foregoing candidates, by
affirmative votes by a majority of the votes of the shares.

Proposal 2:

Approve an amendment to the Ionis Pharmaceuticals, Inc.
2011 Equity Incentive Plan:

FOR	AGAINST	ABSTAIN	BROKER NON-VOTES
81,668,509	11,359,170	166,972	21,105,539

The Companys stockholders approved the foregoing proposal.

Proposal 3:

Approval, on an advisory basis, of the compensation paid
to the Companys executive officers, including the
following resolution:

RESOLVED, that Ionis stockholders approve, on an advisory basis,
the compensation of the named executive officers, as disclosed in
this Proxy Statement for the 2017 Annual Meeting of Stockholders
to the compensation disclosure rules of the Securities and
Exchange Commission.

FOR	AGAINST	ABSTAIN	BROKER NON-VOTES
59,649,475	33,275,149	270,027	21,105,539

The Companys stockholders approved the foregoing proposal.

Proposal 4:

Approval, on an advisory basis, of the frequency of
holding an advisory vote on executive compensation:

1 YEAR	2 YEARS	3 YEARS	ABSTAIN
92,187,838	272,627	624,013	110,173

Based on the results of this vote, and consistent with the
recommendation of the Companys Board of Directors, the Company
will hold an advisory vote on executive compensation on an annual
basis until the next required vote on the frequency of holding
such an advisory vote, which is required at least once every six
years.

Proposal 5:

Ratify the Audit Committee’s selection of Ernst Young
LLP as independent auditors for our 2017 fiscal year:

FOR	AGAINST	ABSTAIN	BROKER NON-VOTES
112,038,206	2,075,791	186,193

The Companys stockholders approved the foregoing proposal.

About IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS)
Ionis Pharmaceuticals, Inc., formerly Isis Pharmaceuticals, Inc., is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform. The Company’s Akcea Therapeutics segment consists of the operations of its subsidiary, Akcea Therapeutics, Inc., which develops and commercializes drugs for cardiometabolic disorders. The Company is developing transformational drugs, which include nusinersen, IONIS-TTR and volanesorsen that are designed to treat patients with orphan diseases. In addition to its Phase III programs, the Company has a pipeline of drugs in Phase II development, which includes IONIS-FXI and IONIS-APO(a)-L. Its Phase II pipeline includes drugs to treat patients with severe and rare diseases, viral infections, ocular diseases, metabolic disorders and cardiovascular diseases. IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) Recent Trading Information
IONIS PHARMACEUTICALS, INC. (NASDAQ:IONS) closed its last trading session down -1.40 at 44.98 with 828,550 shares trading hands.